- Shares of Pharmacyclics (PCYC +13%) come off halt and promptly rally double-digits.
- Investors are cheering more positive data from clinical trials of Imbruvica (ibrutinib).
- See: Imbruvica continues to impress as Phase 3 study stopped early
From other sites
at CNBC.com (Jan 13, 2015)
at CNBC.com (Dec 5, 2014)
at CNBC.com (Sep 17, 2014)
at CNBC.com (Jul 29, 2014)
at CNBC.com (Jul 23, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs